PEOPLE - Changes at Interleukin Genetics:
This article was originally published in Clinica
Interleukin Genetics, a Waltham, Massachusetts-based developer of gene-based inflammatory response risk-assessment and pharmacogenetic tests, has announced changes to its executive management team. Kenneth Kornman, founder, president and chief scientific officer, will also assume the role of CEO, replacing Philip Reilly, who continues as chairman of the board of directors; and Gregg Mayer, most recently the vice-president of strategic marketing and communications at EPIC Pharmaceuticals, has been appointed as chief business officer.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.